Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of $0.65, $0.10 better than the analyst estimate of $0.55. Revenue for the quarter came in at $52.6 million versus the consensus estimate of $58.07 million.

“We achieved the first of our 2020 milestones with today’s announcement of positive data in healthy subjects with EDP-514, our core inhibitor for HBV. EDP-514 was found to be safe and well-tolerated in healthy adults, with a pharmacokinetic profile that demonstrated good blood levels to support once daily dosing. These results support further clinical evaluation, so we have initiated part 2 of the study in nuc-suppressed chronic HBV patients,” stated Jay R. Luly, Enanta President and CEO. “We look forward to reporting further clinical results and updates from our other wholly-owned clinical programs in RSV, NASH and PBC in 2020.”

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.